Proteinuria: abate or applaud abatacept in proteinuric kidney disease?
Jochen Reiser1, Nada Alachkar2
1Department of Medicine, Rush University Medical Center, 1735 West Harrison Street, Cohn Building, Suite 724, Chicago, IL 60612, USA.
Abstract:
T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
09:43Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease III: Interprofessional Care
Diabetic Nephropathy
Nephrotic Syndrome III : Nursing Management
